Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3CNS 1

Conditions

Head and Neck Neoplasms 5Thyroid Neoplasms 4Thyroid Carcinoma, Anaplastic 4Salivary Gland Neoplasms 3Carcinoma, Medullary 2Waldenstrom Macroglobulinemia 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Oropharyngeal Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Myeloma 1Mouth Neoplasms 1Mesothelioma, Malignant 1Medulloblastoma 1

Interventions

Cisplatin 19Docetaxel 17Cetuximab 12Carboplatin 12Radiotherapy 11Magnetic Resonance Spectroscopy 10Biopsy 10pembrolizumab 9Paclitaxel 9Radiotherapy, Intensity-Modulated 8Immunohistochemistry 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Chemotherapy, Adjuvant 7Specimen Handling 6Radiotherapy, Conformal 5Radiosurgery 5Gene Expression Profiling 5Fluorodeoxyglucose F18 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Polymerase Chain Reaction 4Nivolumab 4Bevacizumab 4trastuzumab deruxtecan 3sargramostim 3bicalutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Doxorubicin × Head & Neck × Clear all
NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
149 enrolled
Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT00509665 2018-07-12

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

Medical University of South Carolina

Phase 2 Completed
18 enrolled 9 charts
CNSHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00077428 2013-01-24

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡